Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORL-2-307-ADC in advanced solid tumors
NCT05156866Phase 1Active, not recruiting
- Sponsor
- TORL BioTherapeutics
- Start
- Feb 2022
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 1, open-label trial of TORL-2-307-ADC in gastric cancer (GC), pancreatic cancer (PC), gastroesophageal junction adenocarcinoma and 1 more (2 arms), sponsored by TORL BioTherapeutics. Primary endpoints: Adverse Events at 2 years, Maximum Tolerated Dose at 28 days and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
TORL-2-307-ADC
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)gastroesophageal junction adenocarcinomasolid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05156866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156866.